The purpose of this cross-sectional study was to assess the sociodemographics, disease burden, and treatment patterns patients with episodic chronic migraine in United States.Migraine is a disabling neurological that places an enormous burden on patients.Data were drawn from Adelphi Migraine States Disease Specific Programme (index period: January March 2014). Physicians (N = 150) completed patient report form 10 consulting migraine. Episodic migraineurs had ≤14 headache days per month (HDM)...

Objective To characterize demographics, clinical characteristics, and treatment patterns of patients with cluster headache (CH). Background CH is an uncommon trigeminal autonomic cephalalgia limited evidence‐based options. Patients suffer from extremely painful unilateral attacks symptoms episodic chronic cycles. Design/Methods This retrospective analysis used insurance claims Truven Health Analytics MarketScan ® research databases 2009 to 2014. Two cohorts were compared: (with ≥2 claims)...

Background Efficacy of galcanezumab in chronic migraine has been demonstrated a pivotal Phase 3 study. Here, we assess efficacy patients who have failed ≥2 and ≥1 prior preventives for and/or safety reasons, those never failed. Study design/methods REGAIN (NCT02614261) was 3, randomized, double-blind, placebo-controlled study with migraine. Patients were randomized 2:1:1 to receive placebo, 120 mg/240 mg once monthly during double-blind treatment period lasting three months. Subgroup...

Abstract Objective To evaluate changes in interictal burden with galcanezumab versus placebo patients episodic (EM) or chronic migraine (CM). Background The disruptive effects of occur both during attacks (ictal period) and between (interictal period), affecting work, school, family, social life. Migraine clinical trials typically assess ictal endpoints, neglecting burden. Methods CONQUER was a 3‐month, double‐blind study that randomized adult EM CM who had experienced failure two to four...

Migraine is a common and disabling neurological disease associated with substantial economic burden. Among patients migraine, it unknown if cost differences exist when preventive migraine medication (PMM) switches occur.

To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated galcanezumab or placebo.Patients episodic (4-14 monthly headache days) were either (Evaluation LY2951742 the Prevention Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 208; EVOLVE-2: 226, 220) placebo (EVOLVE-1 425; EVOLVE-2 450) during 6 months treatment. Migraine-Specific Quality Life Questionnaire v2.1 (MSQv2.1) measured effect on patient...

This retrospective claims database study examined the prevalence of mortality and morbidity among adults with type 2 diabetes (T2D) obesity. The used deidentified data from 2007 to 2021 Optum® Market Clarity Dataset. A cohort T2D obesity were identified, age- sex-adjusted rates calculated for mortality, a composite cardiovascular outcome (CCO), microvascular (CMO), other complications. Results overall by class (class 1, 2, 3). For 15,970 included in study, CCO CMO after 5 years was 15.3%...

Abstract Objective To evaluate the measurement properties of all three domains Migraine‐Specific Quality Life questionnaire version 2.1 (MSQ v2.1) electronic patient‐reported outcome (ePRO) to assess functional impact migraine in patients with episodic or chronic (CM); and identify meaningful within‐patient change thresholds for Role Function‐Restrictive (RFR), Function‐Preventive (RFP), Emotional Function (EF) domains. Methods Data were drawn from double‐blind, placebo‐controlled,...

Abstract Objective – To evaluate 12‐week changes from baseline of 2 disease‐specific patient‐reported outcome (PRO) measures in adults with migraine treated galcanezumab, an investigational humanized antibody binding calcitonin gene‐related peptide (CGRP), or placebo. Background Preventing headache‐related functional impairment is important goal preventive treatment and a measurement target for PROs. Understanding which drugs have the potential to improve patient functioning addition...

Effects of galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, on patient satisfaction, health care resource utilization (HCRU), and acute medication use were evaluated in long-term, open-label study patients with migraine.Patients episodic (78.9%) or chronic migraine (21.1%) the CGAJ study, an 12-month treatment period. Galcanezumab 120 mg (with loading dose 240 mg) was administered subcutaneously once month during A self-rated scale, Patient Satisfaction Medication...

To estimate direct and indirect costs in patients with a diagnosis of cluster headache the US.Adult (18-64 years age) enrolled Marketscan Commercial Medicare Databases ≥2 non-diagnostic outpatient (≥30 days apart between two claims) or ≥1 inpatient diagnoses (ICD-9-CM code 339.00, 339.01, 339.02) January 1, 2009 June 30, 2014, were included analyses. Patients had ≥6 months continuous enrollment medical pharmacy coverage before after index date (first diagnosis). Three outcomes evaluated: (1)...

To assess the measurement properties of Migraine-Specific Quality Life Questionnaire version 2.1 (MSQv2.1) electronic patient-reported outcome (ePRO) Role Function-Restrictive (RFR) domain to evaluate functional impact migraine in patients with episodic (EM) or chronic (CM) enrolled clinical trials.

Migraine has a severe impact on health-related quality of life (HRQoL) affecting physical, emotional, and social aspects daily living an individual. Preventive treatment been demonstrated to improve HRQoL by reducing the frequency migraine headache days. The study used data from 2017 Adelphi Disease Specific Program, which is cross-sectional survey physicians their consulting patients with in United States (US) five European countries (EU [Germany, France, UK, Italy Spain]). Objectives were...

Abstract Purpose To evaluate secondary outcomes including changes in functioning and disability associated with galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, patients chronic migraine. Methods Patients randomly received galcanezumab (120 mg n = 278, 240 277) or placebo ( 558) during 3 months of double-blind treatment, followed by 9-month open-label extension. The Migraine-Specific Quality-of-Life Questionnaire v2.1 (MSQv2.1) measured the impact migraine on...

BACKGROUND: Patients with migraine, particularly multiple prior preventive treatment failures, often have high rates of acute headache medication use and are at risk for overuse (acute or symptomatic between 10 15 days per month [depending on the medication] > 3 months). Furthermore, these patients greater health care resource utilization (HCRU). OBJECTIVE: To examine HCRU galcanezumab compared placebo in a population migraine failures. METHODS: In 3-month double-blind phase, episodic...

Aim: Within a treated migraine population, to evaluate if the sub-group meeting criteria for high disease-specific total costs is significantly different with medium and/or low-costs, and identify associated risk factors. Methods: Data from Household Component of Medical Expenditure Panel Survey (MEPS-HC, 2008-2012), nationally representative survey non-institutionalized civilians in US, were analyzed. Key inclusion diagnosis (ICD-9 code: 346.XX) prescribed treatment migraine. Patients...

A concept elicitation, cognitive debriefing, and usability study was undertaken to: 1) ascertain the migraine experience with a particular focus on impact roles daily functioning; 2) determine comprehensiveness comprehensibility of Migraine-Specific Quality Life Questionnaire version 2.1 electronic patient-reported outcome Role Function-Restrictive (MSQ v2.1 ePRO RFR) domain items, appropriateness understanding recall period, response options, instructions; 3) assess an tablet device. Eleven...

This research examines the prevalence of morbidity and mortality among people with obesity or without prediabetes.This observational study uses Optum® Market Clarity deidentified data from 2007 to 2020. Individuals prediabetes (obesity only) were matched 1:1 adults plus based upon age, sex, race, ethnicity, region. Age sex adjusted rates 95 % CIs calculated for each 365-day period post index date over entire 5-year post-period.After 5-years, rate was 10.1 6.9 only (p < 0.05). Five years...

Abstract Background No available studies demonstrate validity and meaningful change thresholds of Work Productivity Activity Impairment (WPAI) questionnaire in patients with migraine. In this post-hoc analysis, we assessed reliability, validity, responsiveness, within-patient from baseline to Month 3 for domain scores episodic migraine (EM) or chronic (CM). Method The Phase 3, multicenter, randomized, double-blind, placebo-controlled CONQUER study (NCT03559257, N = 462) enrolled EM CM who...

The purpose of this study was to describe demographic and clinical characteristics among patients who have medical encounters for weight management treatments investigate the association those with treatment modality.This a retrospective database using claims, pharmacy enrollment information from commercial Medicare Advantage Part D members in Optum Research Database 01/01/2011-2/29/2020. Adult claim 01/01/2012-2/28/2019 were categorized into cohorts according highest intensity intervention...

"Dual diagnoses" of substance abuse and mental illness disorders are common both in psychiatric treatment settings. Recent studies have demonstrated that specific diagnostic categories implications for outcomes dually disordered patients, but a standard has not emerged. The present study compared lay-administered DIS diagnoses with clinical patients state hospital program "dual patients. Categories showed weak association diagnoses. Several frequent were made clinically vice versa....

In response to a mandate imposed by the County Community Mental Health Board, psychosocial rehabilitation agency proposed that its consumer group would develop their own functional level scale measure effectiveness of services provided. The paper describes development and procedures used examine reliability validity. findings suggest Living Skills Scale developed Client Oriented Program Evaluation (COPE) taps all relevant areas in regard levels chronically mentally ill community is high.

This study assessed treatment patterns, disease burden, outcomes, and unmet needs among patients with episodic migraine (EM) in China using Adelphi Migraine Disease Specific Programme™ (DSP) real-world data.Migraine is a prevalent debilitating neurological disorder which presents major public health burden globally. Research on characteristics, patterns EM limited.Data were drawn from an existing data set DSP, point-in-time survey conducted (January-June 2014). Internists/neurologists...

ABSTRACT Recent research in the area of foster care has examined a number external factors that may influence family retention. However, insufficient been devoted to question hardiness, or internal strengths families, and how it affect Hardiness families means possess belief they can control events their experience, feel deep commitment, anticipate change as positive challenge. Additionally, hardy exhibit confidence abilities. Utilizing Family Index, this reports findings from study 82 one...

Background Cluster headache (CH) is a primary disorder associated with low levels of diagnosis and high unmet medical need. The pain attacks, anxiety, fear in anticipation the attacks are extremely debilitating to patient CH. For acute therapy, treatment guidelines recommend inhalation flow oxygen during period an attack. However, use for CH remains largely underutilized. Objectives objectives study, which covered each US states, were map current market landscape grade develop cost simulator...